News & Updates
Filter by Specialty:

First-line biologic therapy persists longer than later agents in ankylosing spondylitis
Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.
First-line biologic therapy persists longer than later agents in ankylosing spondylitis
22 Feb 2022
NOACs preferable over warfarin in AF patients with bioprosthetic valves
Use of nonvitamin K oral anticoagulants (NOACs) results in a reduced incidence of thromboembolic events and major bleeding relative to warfarin in patients with atrial fibrillation (AF) and bioprosthetic valves or valve repair, suggests a study.
NOACs preferable over warfarin in AF patients with bioprosthetic valves
22 Feb 2022
Proinflammatory diet ups risk of nonalcoholic fatty liver disease
A dietary pattern with high inflammatory potential contributes to an increased risk of nonalcoholic fatty liver disease (NAFLD), a recent study has shown.
Proinflammatory diet ups risk of nonalcoholic fatty liver disease
22 Feb 2022
Why do some PCR-negative patients test positive on COVID-19 blood tests?
Serological assays for the coronavirus disease 2019 (COVID-19) sometimes show contradictory findings when compared with nasopharyngeal swab polymerase chain reaction (PCR) tests, according to a recent Singapore study. In particular, even PCR-negative patients with no known exposure could test positive for antibodies.
Why do some PCR-negative patients test positive on COVID-19 blood tests?
22 Feb 2022
Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH
Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.
Add-on lenacapavir helps maintain virologic suppression in treatment-naïve PWH
21 Feb 2022
Antibody cocktail may help relieve burden from hospitals
Ronapreve, also known as REGEN-COV, appears to reduce the risk of hospitalization or the need for additional treatment among COVID-19 patients when used in a real-world setting, a study has shown. The therapy is seen as a promising way to minimize the impact of SARS-CoV-2 infection on the public healthcare system.
Antibody cocktail may help relieve burden from hospitals
21 Feb 2022
Elevated dietary glycaemic index, load linked to higher CVD mortality risk
Dietary patterns with higher glycaemic index (GI) and glycaemic load (GL) appear to elevate the risk of cardiovascular disease (CVD) mortality, according to a study on Chinese adults.